DDInter712 DDInter1658
Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Famotidine {u} (Compound) binds {v} (Gene) SLC47A1
Famotidine {u} (Compound) upregulates {v} (Gene) IFNAR1
Famotidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Famotidine {u} (Compound) downregulates {v} (Gene) PCNA
Famotidine {u} (Compound) causes {v} (Side Effect) Jaundice
Famotidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Famotidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ketorolac
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Famotidine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Famotidine (Compound) binds SLC47A1 (Gene)
Famotidine (Compound) upregulates IFNAR1 (Gene)
Famotidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Famotidine (Compound) downregulates PCNA (Gene)
Famotidine (Compound) causes Jaundice (Side Effect)
Famotidine may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Famotidine may cause a minor interaction that can limit clinical effects when taken with Ketorolac
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine
Famotidine may lead to a major life threatening interaction when taken with Dasatinib